Quick Summary

Chasteberry (Vitex agnus-castus) is a plant traditionally used for managing menstrual disorders such as premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), menstrual irregularities, mastalgia, and features of polycystic ovary syndrome (PCOS). Clinical evidence from several randomized controlled trials and systematic reviews suggests potential benefits in reducing PMS symptoms and improving some hormonal and metabolic markers in PCOS. However, the quality of evidence varies, and further well-designed clinical trials are needed to establish efficacy and safety profiles. Chasteberry extracts are generally well tolerated with mild reported adverse effects.

What is it?

Chasteberry, also known by its Latin name Vitex agnus-castus, is a deciduous shrub native to the Mediterranean region and Central Asia. The dried berries of this plant have been used traditionally in herbal medicine, primarily related to female reproductive health.

Traditional Uses

  • Management of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD)
  • Alleviation of menstrual irregularities and dysmenorrhea
  • Reduction of cyclic mastalgia (breast pain)
  • Support for symptoms associated with polycystic ovary syndrome (PCOS)
  • Control of mild hyperprolactinaemia

Active Compounds

Vitex agnus-castus contains several biologically active compounds including flavonoids, iridoid glycosides, diterpenoids, and essential oils. These constituents are thought to influence hormonal pathways, particularly through dopaminergic effects.

Potential Benefits with Evidence Levels

  • Reduction of PMS and PMDD symptoms: Moderate-certainty evidence from multiple randomized controlled trials (RCTs) and systematic reviews suggests that Vitex agnus-castus preparations may be effective and safe in alleviating PMS and PMDD symptoms. However, some studies show high risk of bias and heterogeneity. (PMID: 29063202, 28237870, 38075075)
  • Improvement in clinical manifestations of PCOS: Limited clinical evidence from recent randomized, double-blind controlled trials indicates possible improvements in oxidative stress markers, insulin resistance, lipid profile, hirsutism scores, and menstrual frequency in women with PCOS. Animal studies support potential endocrine benefits. More extensive human research is needed. (PMID: 41428718, 42011344, 40783741, 36648830)
  • Management of mild hyperprolactinaemia: Some case series and small studies suggest Vitex agnus-castus may reduce serum prolactin levels potentially via dopaminergic activity, but large RCTs are lacking. (PMID: 38075075)
  • Reduction of cyclic mastalgia severity: Meta-analyses indicate potential benefit of Vitex agnus-castus and other herbs in reducing cyclic mastalgia symptoms, though evidence quality is limited. (PMID: 36446563)
  • Improvement in menstrual cycle disorders and quality of life: Retrospective data from a cohort of 1700 women showed improvements in dysmenorrhea, mastalgia, menstrual bleeding patterns, and quality of life after three months of treatment with Vitex agnus-castus. Safety was favorable. (PMID: 38393671)

Side Effects

Vitex agnus-castus is generally well tolerated. Reported adverse effects are usually mild and include:

  • Mild gastrointestinal symptoms such as nausea and abdominal discomfort
  • Rare skin reactions including pruritus, rash, and urticaria
  • Occasional reports of tiredness, headache, and dry mouth
  • No significant adverse effects on infants have been observed in studies

Drug Interactions

Data on drug interactions with Vitex agnus-castus are limited. Due to its possible dopaminergic activity, it could theoretically interact with dopamine agonists or antagonists. Case reports have suggested potential interaction with norethisterone. Until more robust data are available, caution is advised when combining Vitex with other medications affecting hormonal or dopaminergic systems.

Who Should Avoid It

Contraindications are not well established owing to insufficient research. Caution is advised for:

  • Individuals taking dopaminergic agents
  • People with hormone-sensitive conditions
  • Pregnant or breastfeeding women, as safety data are lacking and some animal studies suggest potential risks

Evidence Limitations

  • Many clinical trials have a high risk of bias, small sample sizes, and methodological variability
  • Heterogeneity and publication bias complicate interpretation of meta-analyses
  • Diverse preparations and dosing regimens limit generalizability
  • Lack of large, rigorous randomized placebo-controlled trials for many indications
  • Limited long-term safety and drug interaction data, especially in pregnancy

References

Last Reviewed

June 2024

Informational Disclaimer: This page is for informational purposes only. It does not provide medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting any new supplement or therapy, especially if you have underlying health conditions or are taking other medications.